BioMarin Pharmaceutical (BMRN) News Today $63.93 -0.41 (-0.64%) Closing price 02/7/2025 04:00 PM EasternExtended Trading$63.93 0.00 (0.00%) As of 02/7/2025 06:39 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrends All Sources Trusted Sources MarketBeat Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 April 2022 March 2022 Time Period BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) Receives Average Recommendation of "Moderate Buy" from AnalystsShares of BioMarin Pharmaceutical Inc. (NASDAQ:BMRN - Get Free Report) have been given an average recommendation of "Moderate Buy" by the twenty-three research firms that are currently covering the firm, MarketBeat reports. Seven analysts have rated the stock with a hold rating, fifteen have assignFebruary 8 at 1:51 AM | marketbeat.comBioMarin Pharmaceutical Inc. Announces Upcoming Financial Results Conference CallFebruary 5 at 10:25 AM | gurufocus.comBioMarin to Host Fourth Quarter and Full-Year 2024 Financial Results Conference Call and Webcast on Wednesday, February 19, 2025, at 4:30pm ETFebruary 5 at 9:00 AM | prnewswire.comabrdn plc Acquires 168,121 Shares of BioMarin Pharmaceutical Inc. (NASDAQ:BMRN)abrdn plc increased its stake in BioMarin Pharmaceutical Inc. (NASDAQ:BMRN - Free Report) by 31.9% in the 4th quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 695,802 shares of the biotechnology company's stock after aFebruary 5 at 4:47 AM | marketbeat.comMediolanum International Funds Ltd Makes New Investment in BioMarin Pharmaceutical Inc. (NASDAQ:BMRN)Mediolanum International Funds Ltd bought a new position in shares of BioMarin Pharmaceutical Inc. (NASDAQ:BMRN - Free Report) in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund bought 18,939 shares of the biotechnFebruary 3, 2025 | marketbeat.comRobeco Institutional Asset Management B.V. Trims Position in BioMarin Pharmaceutical Inc. (NASDAQ:BMRN)Robeco Institutional Asset Management B.V. cut its stake in shares of BioMarin Pharmaceutical Inc. (NASDAQ:BMRN - Free Report) by 58.9% during the fourth quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm owned 86,574 shares of the biFebruary 3, 2025 | marketbeat.comLevel Wealth Management LLC Buys Shares of 9,543 BioMarin Pharmaceutical Inc. (NASDAQ:BMRN)Level Wealth Management LLC purchased a new position in BioMarin Pharmaceutical Inc. (NASDAQ:BMRN - Free Report) during the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor purchased 9,543 shares of the bioteFebruary 2, 2025 | marketbeat.comBioMarin Pharmaceutical Inc. (NASDAQ:BMRN) Shares Acquired by Swedbank ABSwedbank AB increased its position in BioMarin Pharmaceutical Inc. (NASDAQ:BMRN - Free Report) by 11.2% in the fourth quarter, according to its most recent disclosure with the SEC. The institutional investor owned 432,122 shares of the biotechnology company's stock after purchasing an additional 4January 31, 2025 | marketbeat.comIs BioMarin Pharmaceutical (BMRN) the Best Depressed Stock to Invest in Now?January 27, 2025 | msn.comMerit Financial Group LLC Takes Position in BioMarin Pharmaceutical Inc. (NASDAQ:BMRN)Merit Financial Group LLC acquired a new position in shares of BioMarin Pharmaceutical Inc. (NASDAQ:BMRN - Free Report) in the fourth quarter, according to its most recent filing with the Securities & Exchange Commission. The firm acquired 4,819 shares of the biotechnology company's stock, valuJanuary 25, 2025 | marketbeat.comBioMarin Pharmaceuticals: Share Downdraft Combined With VOXZOGO Potential Makes A BuyJanuary 23, 2025 | seekingalpha.comZacks.com featured highlights include BioMarin, Amazon.com, Leidos and The EnsignJanuary 23, 2025 | finance.yahoo.comCantor Fitzgerald Forecasts BMRN FY2025 EarningsBioMarin Pharmaceutical Inc. (NASDAQ:BMRN - Free Report) - Stock analysts at Cantor Fitzgerald issued their FY2025 earnings estimates for shares of BioMarin Pharmaceutical in a research report issued to clients and investors on Tuesday, January 21st. Cantor Fitzgerald analyst O. Brayer anticipateJanuary 22, 2025 | marketbeat.comFort Washington Investment Advisors Inc. OH Cuts Stock Position in BioMarin Pharmaceutical Inc. (NASDAQ:BMRN)Fort Washington Investment Advisors Inc. OH trimmed its position in BioMarin Pharmaceutical Inc. (NASDAQ:BMRN - Free Report) by 1.7% during the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 715,500 shares ofJanuary 22, 2025 | marketbeat.comEarnings are growing at BioMarin Pharmaceutical (NASDAQ:BMRN) but shareholders still don't like its prospectsJanuary 21, 2025 | finance.yahoo.comBioMarin Pharmaceutical Inc. (BMRN) Stock: The Under-the-Radar Stock Poised for Massive Upside in 2025January 21, 2025 | msn.comAvanza Fonder AB Buys Shares of 16,156 BioMarin Pharmaceutical Inc. (NASDAQ:BMRN)Avanza Fonder AB purchased a new position in BioMarin Pharmaceutical Inc. (NASDAQ:BMRN - Free Report) during the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund purchased 16,156 shares of the biotechnology company's stock,January 20, 2025 | marketbeat.comBioMarin Pharmaceutical Inc. (NASDAQ:BMRN) Sees Large Decrease in Short InterestBioMarin Pharmaceutical Inc. (NASDAQ:BMRN - Get Free Report) was the target of a significant decline in short interest in the month of December. As of December 31st, there was short interest totalling 4,540,000 shares, a decline of 12.9% from the December 15th total of 5,210,000 shares. Based on an average daily volume of 1,420,000 shares, the short-interest ratio is currently 3.2 days.January 18, 2025 | marketbeat.comBioMarin Pharmaceutical (NASDAQ:BMRN) Stock Price Down 3% - Should You Sell?BioMarin Pharmaceutical (NASDAQ:BMRN) Trading Down 3% - Time to Sell?January 17, 2025 | marketbeat.comBioMarin Pharmaceutical Target of Unusually High Options Trading (NASDAQ:BMRN)BioMarin Pharmaceutical Inc. (NASDAQ:BMRN - Get Free Report) was the target of unusually large options trading activity on Friday. Stock investors purchased 9,057 put options on the stock. This is an increase of 254% compared to the typical daily volume of 2,557 put options.January 17, 2025 | marketbeat.comBioMarin Pharmaceutical Inc. (NASDAQ:BMRN) Shares Acquired by Assenagon Asset Management S.A.Assenagon Asset Management S.A. raised its position in BioMarin Pharmaceutical Inc. (NASDAQ:BMRN - Free Report) by 461.3% during the 4th quarter, according to its most recent filing with the SEC. The firm owned 611,667 shares of the biotechnology company's stock after buying an additional 502,695 sJanuary 17, 2025 | marketbeat.comBioMarin stock touches 52-week low at $60.77 amid challengesJanuary 17, 2025 | msn.comBioMarin Pharmaceutical (NASDAQ:BMRN) Reaches New 52-Week Low - What's Next?BioMarin Pharmaceutical (NASDAQ:BMRN) Sets New 52-Week Low - Time to Sell?January 16, 2025 | marketbeat.comBioMarin Pharmaceutical (BMRN) Receives a Buy from JefferiesJanuary 16, 2025 | markets.businessinsider.comWedmont Private Capital Makes New $430,000 Investment in BioMarin Pharmaceutical Inc. (NASDAQ:BMRN)Wedmont Private Capital acquired a new stake in BioMarin Pharmaceutical Inc. (NASDAQ:BMRN - Free Report) during the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund acquired 6,376 shares of the biotechnology company's stock, valueJanuary 16, 2025 | marketbeat.comBioMarin Pharmaceutical (NASDAQ:BMRN) Shares Down 3% - What's Next?BioMarin Pharmaceutical (NASDAQ:BMRN) Trading Down 3% - Here's WhyJanuary 15, 2025 | marketbeat.com3 Niche Biotech Stocks Redefining InnovationJanuary 15, 2025 | stocknews.comBioMarin Pharmaceutical: Strong Revenue Growth and Robust Pipeline Drive Buy RatingJanuary 15, 2025 | markets.businessinsider.comBioMarin Pharmaceutical’s Growth Potential: Overcoming Challenges with Strategic Leadership and Global ExpansionJanuary 15, 2025 | markets.businessinsider.comBernstein Remains a Buy on BioMarin Pharmaceutical (BMRN)January 14, 2025 | markets.businessinsider.comBioMarin Pharmaceutical Inc. (NASDAQ:BMRN) Receives Consensus Recommendation of "Moderate Buy" from AnalystsShares of BioMarin Pharmaceutical Inc. (NASDAQ:BMRN - Get Free Report) have received an average recommendation of "Moderate Buy" from the twenty-three analysts that are currently covering the company, Marketbeat.com reports. Seven research analysts have rated the stock with a hold recommendation, fJanuary 14, 2025 | marketbeat.comBioMarin Pharmaceutical’s Promising Growth and Strategic Outlook Justifies Buy RatingJanuary 14, 2025 | markets.businessinsider.comHold Rating for BioMarin: Balancing Patent Litigation and Pipeline ProspectsJanuary 14, 2025 | markets.businessinsider.comBioMarin initiates legal action against Ascendis over patent infringementJanuary 13, 2025 | markets.businessinsider.comBioMarin Announces Legal Action Against Ascendis Pharma A/S in European Unified Patent CourtJanuary 13, 2025 | prnewswire.comZacks Research Issues Positive Outlook for BMRN EarningsBioMarin Pharmaceutical Inc. (NASDAQ:BMRN - Free Report) - Analysts at Zacks Research lifted their Q2 2025 earnings per share estimates for BioMarin Pharmaceutical in a report released on Wednesday, January 8th. Zacks Research analyst S. Ganoria now anticipates that the biotechnology company willJanuary 13, 2025 | marketbeat.comZacks Research Brokers Raise Earnings Estimates for BMRNBioMarin Pharmaceutical Inc. (NASDAQ:BMRN - Free Report) - Stock analysts at Zacks Research boosted their Q1 2025 earnings per share estimates for shares of BioMarin Pharmaceutical in a research note issued to investors on Wednesday, January 8th. Zacks Research analyst S. Ganoria now forecasts thJanuary 10, 2025 | marketbeat.comBernstein Sticks to Its Buy Rating for BioMarin Pharmaceutical (BMRN)January 8, 2025 | markets.businessinsider.comBioMarin Pharmaceutical (NASDAQ:BMRN) Trading 2.4% Higher - Still a Buy?BioMarin Pharmaceutical (NASDAQ:BMRN) Trading 2.4% Higher - Here's What HappenedJanuary 8, 2025 | marketbeat.comBioMarin Pharmaceutical Inc. to Present at J.P. Morgan Healthcare ConferenceJanuary 6, 2025 | gurufocus.comBioMarin to Present at the 43rd Annual J.P. Morgan Healthcare Conference on Monday, January 13, at 9:00 am PT / 12:00 pm ET, in San Francisco, CAJanuary 6, 2025 | prnewswire.com10 Magnificent Stocks That Can Make You Richer in 2025January 3, 2025 | fool.comBioMarin Pharmaceutical Inc. (NASDAQ:BMRN) Sees Significant Decline in Short InterestBioMarin Pharmaceutical Inc. (NASDAQ:BMRN - Get Free Report) was the recipient of a significant drop in short interest during the month of December. As of December 15th, there was short interest totalling 5,210,000 shares, a drop of 9.4% from the November 30th total of 5,750,000 shares. Based on an average daily volume of 1,470,000 shares, the short-interest ratio is currently 3.5 days.December 31, 2024 | marketbeat.comFirst Week of February 2025 Options Trading For BioMarin Pharmaceutical (BMRN)December 26, 2024 | nasdaq.comBioMarin Pharmaceutical Inc. (NASDAQ:BMRN) Stock Holdings Lessened by Principal Financial Group Inc.Principal Financial Group Inc. lessened its holdings in shares of BioMarin Pharmaceutical Inc. (NASDAQ:BMRN - Free Report) by 29.5% in the third quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund owned 458,039 shares of the biotechnolDecember 24, 2024 | marketbeat.comStifel Financial Corp Has $2.15 Million Stake in BioMarin Pharmaceutical Inc. (NASDAQ:BMRN)Stifel Financial Corp lowered its stake in shares of BioMarin Pharmaceutical Inc. (NASDAQ:BMRN - Free Report) by 30.6% during the third quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund owned 30,537 shares of the biotechnology compDecember 20, 2024 | marketbeat.comBioMarin Pharmaceutical Inc. (NASDAQ:BMRN) Given Average Rating of "Moderate Buy" by AnalystsShares of BioMarin Pharmaceutical Inc. (NASDAQ:BMRN - Get Free Report) have received an average recommendation of "Moderate Buy" from the twenty-three ratings firms that are currently covering the stock, Marketbeat reports. Seven equities research analysts have rated the stock with a hold rating, fDecember 20, 2024 | marketbeat.comNational Bank of Canada FI Decreases Stock Position in BioMarin Pharmaceutical Inc. (NASDAQ:BMRN)National Bank of Canada FI trimmed its position in shares of BioMarin Pharmaceutical Inc. (NASDAQ:BMRN - Free Report) by 93.6% in the 3rd quarter, according to its most recent disclosure with the SEC. The institutional investor owned 919 shares of the biotechnology company's stock after selling 13December 18, 2024 | marketbeat.comTidal Investments LLC Increases Stake in BioMarin Pharmaceutical Inc. (NASDAQ:BMRN)Tidal Investments LLC boosted its stake in shares of BioMarin Pharmaceutical Inc. (NASDAQ:BMRN - Free Report) by 150.4% during the 3rd quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund owned 30,467 shares of the biotechnology company'sDecember 17, 2024 | marketbeat.comBioMarin Pharmaceutical Inc. (NASDAQ:BMRN) Shares Acquired by Geode Capital Management LLCGeode Capital Management LLC boosted its stake in shares of BioMarin Pharmaceutical Inc. (NASDAQ:BMRN - Free Report) by 1.9% in the third quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 3,260,050 shares of the biotechnology company's stDecember 15, 2024 | marketbeat.com Get BioMarin Pharmaceutical News Delivered to You Automatically Sign up to receive the latest news and ratings for BMRN and its competitors with MarketBeat's FREE daily newsletter. Email Address BMRN Media Mentions By Week BMRN Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. BMRN News Sentiment▼1.190.58▲Average Medical News Sentiment BMRN News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. BMRN Articles This Week▼79▲BMRN Articles Average Week Get BioMarin Pharmaceutical News Delivered to You Automatically Sign up to receive the latest news and ratings for BMRN and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies ALNY News Today BIIB News Today UTHR News Today NBIX News Today INCY News Today EXAS News Today EXEL News Today RGEN News Today HALO News Today MDGL News Today Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:BMRN) was last updated on 2/8/2025 by MarketBeat.com Staff From Our PartnersCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | SponsoredDo this Before Elon’s Reveal on April 23rdElon’s newest tech could pay you an extra $30,000 a year — while you sleep. It’s smaller than a quarter but...Brownstone Research | SponsoredTexas approves new currencyRural Texas Town Ramps Up Global Currency War A small town has joined a radical $1.9 trillion attack on the...Stansberry Research | SponsoredCould 1 of these 5 “America First” stocks 26x from here?Tim Bohen says these 5 tiny “America First” stocks are next up in 2025. They’re trading for less than $2 ri...Timothy Sykes | SponsoredElon Musk’s secret rendezvous with Jensen HuangElon Musk is the world's richest person, and it's not even close. Now he's got the ear of President Trump, ...Weiss Ratings | SponsoredSteve Bannon Sounds Alarm On Elon Musk’s ‘Indefensible Betrayal’Now, if Elon Musk was truly an America First champion… His cronies wouldn't be bragging to the New York Tim...Colonial Metals | SponsoredElon’s ‘Agents’ StrikeHe might be the richest man on the planet – but Elon Musk just landed himself a new job... In a move that c...Altimetry | SponsoredThis Crypto Is Set to Explode in JanuaryIt's a groundbreaking opportunity that could be poised for extraordinary gains. The catalyst behind this su...Crypto 101 Media | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding BioMarin Pharmaceutical Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share BioMarin Pharmaceutical With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
